Business Wire

NTT-DOCOMO

16.1.2024 10:11:27 CET | Business Wire | Press release

Share
DOCOMO to Exhibit at MWC Barcelona 2024, World's Largest Mobile Exhibition

NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2024, the world's largest mobile exhibition, in Barcelona, Spain from February 26 to 29. DOCOMO's booth will showcase exhibits of its technological advancement since last year and presentations focused on the core themes of 6G, open radio access networks (Open RAN) and extended reality (XR), aiming to advance international standardization and foster global business opportunities with the implementation of next-generation communication technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116090399/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

NTT DOCOMO Booth at MWC Barcelona 2024 (Graphic: Business Wire)

For 6G, there will be interactive demonstrations of FEEL TECH,® an innovative technology that revolutionizes the sharing of sensory information between people DOCOMO's Human Augmentation Platform connected to a 6G network. This pioneering technology aims to facilitate clear transmission of sensory information that is often difficult to communicate verbally, paving the way for a new communication culture and providing added value for an enhanced quality of life.

The booth will also provide a glimpse of the coming world of 6G and advanced wireless technologies that DOCOMO is now developing, such as a non-terrestrial network (NTN) incorporating high-altitude platform stations (HAPS),1 which are expected to facilitate the broad extension of communication services beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.

For Open RAN, in addition to presenting the OREX®2-branded services (OREX Packages), DOCOMO will introduce the latest initiatives with diverse global vendors and operators since the launch of the OREX to make Open RAN a reality.

For XR, DOCOMO will showcase the first concept model3 of XR glasses from NTT QONOQ Devices, INC.,4 which is scheduled for release around mid-2024, along with images of utilization.

At MWC Barcelona 2024, DOCOMO looks forward to showcasing its cutting-edge technologies and businesses the company is developing under the brand slogan "changing worlds with you."

For more about DOCOMO's exhibits and the overall exhibition, please refer to the appendix.

1 Unmanned vehicles flying in the stratosphere for days or months at a time, using relays to provide mobile connectivity (ranging up to 200 kilometers) in mountainous and remote areas, including at sea and in the air, on a highly cost-efficient basis.
2 OREX Announces OREX® Open RAN Service Lineup https://www.docomo.ne.jp/english/info/media_center/pr/2023/0927_00.html
3 Specifications of final commercial products may differ from the reference exhibits.
4 NTT QONOQ, INC. and SHARP CORPORATION form a joint venture company, NTT QONOQ Devices, INC.
https://www.devices.nttqonoq.com/pdf/20230327.pdf
Human Augmentation Platform, FEEL TECH and OREX are registered trademarks of NTT DOCOMO, INC. in Japan.

About NTT DOCOMO

NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/

Appendix

Overview of NTT DOCOMO Booth at MWC Barcelona 2024

1. Exhibitions

 

Theme

Exhibit & Demo

Details

6G

Wireless technologies and NTN

Non-terrestrial network initiatives for 6G and extended coverage, including technical explanations, dioramas and simulators.

Human Augmentation Platform

Platform and FEEL TECH technology for sharing sensory information between people. 

Open RAN

Virtual tour of Shared Open Lab

360-degree, 3D virtual tour of the OREX verification environment.

Automated network design and maintenance

Demonstrations of actual systems for automated network design and maintenance.

XR

Conceptual model of XR glasses

Mock-up model and video illustrating how these proposed glasses will be used.

2. NTT DOCOMO Booth Location
Hall 4 Stand 4E50

3. Presentation
Tentative title: Open RAN: Toward Commercialization and Operations
When: Monday, February 26 from 13:15 to 13:45 (local time)
Where: Broadcast Stage, Hall 4
Speaker: Mr. Sadayuki Abeta, OREX evangelist, NTT DOCOMO
Note: Content and schedule are subject to change. Please see MWC Barcelona 2024 for the latest information.

Reference

MWC Barcelona 2024
https://www.mwcbarcelona.com/

1. Dates & Times
February 26 to 29
08:30 to 19:00, but 08:30 to 16:00 on last day (all times local)

2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116090399/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye